The metabolic reprogramming and vulnerability of SF3B1 mutations

被引：4
|
作者：
Dalton, W. Brian [1 ]
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, 1650 Orleans St,CRBI Room 285, Baltimore, MD 21231 USA
来源：
MOLECULAR & CELLULAR ONCOLOGY | 2020年 / 7卷 / 03期
关键词：
spliceosome; serine; PHGDH; metabolism;
D O I：
10.1080/23723556.2019.1697619
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Mutations in the splicing factor 3b subunit 1 (SF3B1) gene create a neomorphic protein that disrupts RNA splicing, but the downstream consequences of this missplicing are unclear. Our recent study of isogenic human cells demonstrated that SF3B1(MUT) induces reprogramming of energy metabolism and a targetable vulnerability to deprivation of the nonessential amino acid serine.
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Influence of SF3B1 gene mutation is different from that of Sf3B1 inhibitor in colorectal cancer
    Yamano, Tomoki
    Kubo, Shuji
    Matsubara, Nagahide
    Yano, Aya
    Tomita, Naohiro
    CANCER RESEARCH, 2014, 74 (19)
  • [32] Lack of SF3B1 R625 mutations in cutaneous melanoma
    Bastian Schilling
    Nicola Bielefeld
    Antje Sucker
    Uwe Hillen
    Lisa Zimmer
    Dirk Schadendorf
    Michael Zeschnigk
    Klaus G Griewank
    Diagnostic Pathology, 8
  • [33] COOPERATION BETWEEN SF3B1 MUTATIONS AND ATM DELETION IN CLL DEVELOPMENT
    Cusan, Martina
    Hart, Kevyn
    Iyer, Prajish
    Wang, Lili
    EXPERIMENTAL HEMATOLOGY, 2018, 64 : S60 - S60
  • [34] Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia
    Schwaederle, M.
    Ghia, E.
    Rassenti, L. Z.
    Obara, M.
    Aquila, M. L. Dell'
    Fecteau, J. F.
    Kipps, T. J.
    LEUKEMIA, 2013, 27 (05) : 1214 - 1217
  • [35] SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications
    Damm, F.
    Thol, F.
    Kosmider, O.
    Kade, S.
    Loeffeld, P.
    Dreyfus, F.
    Stamatoullas-Bastard, A.
    Tanguy-Schmidt, A.
    Beyne-Rauzy, O.
    de Botton, S.
    Guerci-Bresler, A.
    Goehring, G.
    Schlegelberger, B.
    Ganser, A.
    Bernard, O. A.
    Fontenay, M.
    Heuser, M.
    LEUKEMIA, 2012, 26 (05) : 1137 - 1140
  • [36] SF3B1 mutations constitute a novel therapeutic target in breast cancer
    Maguire, Sarah
    Leonidou, Andri
    Wai, Patty
    Marchio, Caterina
    Ng, Charlotte
    Sapino, Ana
    Vincent-Salomon, Anne
    Reis-Filho, Jorge
    Weigelt, Britta
    Natrajan, Rachael
    CANCER RESEARCH, 2015, 75 (22)
  • [37] THE INFLUENCE OF SF3B1 MUTATIONS ON THE RESPONSIVENESS OF BLOOD CANCERS TO MOLECULAR THERAPEUTICS
    Liberante, F.
    Lappin, K.
    McMullin, M. -F.
    Savage, K.
    Mills, K.
    HAEMATOLOGICA, 2015, 100 : 236 - 236
  • [38] SF3B1 mutations constitute a novel therapeutic target in breast cancer
    Maguire, Sarah L.
    Leonidou, Andri
    Wai, Patty
    Marchio, Caterina
    Ng, Charlotte K. Y.
    Sapino, Anna
    Salomon, Anne-Vincent
    Reis-Filho, Jorge S.
    Weigelt, Britta
    Natrajan, Rachael C.
    JOURNAL OF PATHOLOGY, 2015, 235 (04): : 571 - 580
  • [39] Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms
    Zuo, Zhuang
    Medeiros, L. Jeffrey
    Garces, Sofia
    Routbort, Mark J.
    Ok, Chi Young
    Loghavi, Sanam
    Kanagal-Shamanna, Rashmi
    Jelloul, Fatima Zahra
    Garcia-Manero, Guillermo
    Chien, Kelly L. S.
    Patel, Keyur S. P.
    Luthra, Rajyalakshmi
    Yin, C. Cameron
    BIOLOGY-BASEL, 2023, 12 (01):
  • [40] SF3B1 MUTATIONS IN CLL ARE ASSOCIATED WITH A DEFECTIVE DNA DAMAGE RESPONSE
    Eldering, E.
    te Raa, D.
    Derks, I.
    Navrkalova, V.
    Skowronska, A.
    Oldreive, C.
    Moerland, P.
    Malcikova, J.
    Trbusek, M.
    Hullein, J.
    Jethwa, A.
    Zenz, T.
    Pospisilova, S.
    Stankovic, T.
    van Oers, M.
    Kater, A.
    HAEMATOLOGICA, 2014, 99 : 315 - 316
12345